{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:31:11Z","timestamp":1783636271827,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T00:00:00Z","timestamp":1628035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T00:00:00Z","timestamp":1628035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>We aim to evaluate the reproductive outcome of fertility-sparing surgery and chemotherapy among young women diagnosed with MOGCT of any stage.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In the current retrospective study we evaluated 79 patients with malignant ovarian germ cell tumors (MOGCT) who visited at Imam Center, Vali-e-asr Hospital, Gynecologic Oncology department during 2001\u20132016. Reproductive outcomes (menstruation status and childbearing) followed fertility-preserving surgery and adjuvant chemotherapy by filling questionnaires. Statistical analysis was done with SPSS software, Chi-Square Tests were done, and significance was determined at <jats:italic>P<\/jats:italic>\u2009\u2264\u20090.05. Results among 79 young women who underwent fertility-sparing treatment, 72 patients followed up for reproductive outcome, and 7 patients excluded because of death (3 cases), XY genotyping (3 cases), and bilateral ovarian involvement (1 case). The mean age at presentation was 23\u00a0years. (Range: 19\u201333\u00a0years). The 5 and 10-year disease-free survival rate was 87% and 94.4%, respectively. The overall survival rate (OSR) was 94.4% at 5 and 10\u00a0years. Regular menstruation recovered in 60 of 72 patients after treatment (83%). All patients without adjuvant chemotherapy experienced regular menstruation, while normal menstruation was retrieved in 78% in the adjuvant chemotherapy group at the end of treatment. This retrieval of regular menstruation was not dependent on the age or number of chemotherapy cycles. 19 of 26 patients who attempted pregnancy were led to delivery (73%). No one required infertility treatments. The mean of chemotherapy cycles is related to a successful pregnancy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We showed patients with MOGCT could become pregnant and give birth if they desire. The advanced tumor stage wasn't the convincing factor for avoiding fertility preservation. Fertility sparing surgery with adjuvant chemotherapy is a safe treatment and results in a high fertility rate.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12905-021-01437-8","type":"journal-article","created":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T09:03:05Z","timestamp":1628067785000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Fertility sparing surgery in malignant ovarian Germ cell tumor (MOGCT): 15\u00a0years experiences"],"prefix":"10.1186","volume":"21","author":[{"given":"Narges","family":"Zamani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohadese","family":"Rezaei Poor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sedigheh","family":"Ghasemian Dizajmehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shima","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitra","family":"Modares Gilani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,4]]},"reference":[{"issue":"2","key":"1437_CR1","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/IGC.0b013e318272e754","volume":"23","author":"SH Shim","year":"2013","unstructured":"Shim SH, Kim DY, Lee SW, Park JY, Kim JH, Kim YM, Kim YT, Nam JH. Laparoscopic management of early-stage malignant nonepithelial ovarian tumors: surgical and survival outcomes. Int J Gynecol Cancer. 2013;23(2):249\u201355. https:\/\/doi.org\/10.1097\/IGC.0b013e318272e754.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"1437_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ygyno.2008.04.022","volume":"110","author":"S Kumar","year":"2008","unstructured":"Kumar S, Shah JP, Bryant CS, Imudia AN, Cote ML, Ali-Fehmi R, Malone JM Jr, Morris RT. The prevalence and prognostic impact of lymph node metastasis in malignant germ cell tumors of the ovary. Gynecol Oncol. 2008;110(2):125\u201332. https:\/\/doi.org\/10.1016\/j.ygyno.2008.04.022.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1437_CR3","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1148\/rg.343130067","volume":"34","author":"AM Shaaban","year":"2014","unstructured":"Shaaban AM, Rezvani M, Elsayes KM, Baskin H Jr, Mourad A, Foster BR, Jarboe EA, Menias CO. Ovarian malignant germ cell tumors: cellular classification and clinical and imaging features. Radiographics. 2014;34(3):777\u2013801. https:\/\/doi.org\/10.1148\/rg.343130067.","journal-title":"Radiographics"},{"issue":"2","key":"1437_CR4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3892\/mco.2016.915","volume":"5","author":"T Zhao","year":"2016","unstructured":"Zhao T, Liu Y, Jiang H, Zhang H, Lu Y. Management of bilateral malignant ovarian germ cell tumors: experience of a single institute. Mol Clin Oncol. 2016;5(2):383\u20137. https:\/\/doi.org\/10.3892\/mco.2016.915.","journal-title":"Mol Clin Oncol"},{"issue":"3","key":"1437_CR5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.ygyno.2017.10.010","volume":"147","author":"D Nasioudis","year":"2017","unstructured":"Nasioudis D, Frey MK, Chapman-Davis E, Caputo TA, Holcomb K. Fertility-preserving surgery for advanced stage ovarian germ cell tumors. Gynecol Oncol. 2017;147(3):493\u20136. https:\/\/doi.org\/10.1016\/j.ygyno.2017.10.010.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1437_CR6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13048-017-0348-x","volume":"10","author":"N Zhang","year":"2017","unstructured":"Zhang N, Chen R, Hua K, Zhang Y. A retrospective study of reproductive outcomes after fertility-sparing surgery and postoperative adjuvant chemotherapy in malignant ovarian germ cell tumors and sex cord-stromal tumors. J Ovarian Res. 2017;10(1):52. https:\/\/doi.org\/10.1186\/s13048-017-0348-x.","journal-title":"J Ovarian Res"},{"issue":"3","key":"1437_CR7","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1006\/gyno.1995.1240","volume":"58","author":"S Culine","year":"1995","unstructured":"Culine S, Lhomme C, Kattan J, Duvillard P, Michel G, Gerbaulet A, Droz JP. Cisplatin-based chemotherapy in dysgerminoma of the ovary: thirteen-year experience at the Institut Gustave Roussy. Gynecol Oncol. 1995;58(3):344\u20138. https:\/\/doi.org\/10.1006\/gyno.1995.1240.","journal-title":"Gynecol Oncol"},{"issue":"17","key":"1437_CR8","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1200\/JCO.2004.01.006","volume":"22","author":"PC Rogers","year":"2004","unstructured":"Rogers PC, Olson TA, Cullen JW, Billmire DF, Marina N, Rescorla F, Davis MM, London WB, Lauer SJ, Giller RH, Cushing B. Pediatric Oncology Group 9048; Children\u2019s Cancer Group 8891. Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9048 and Children\u2019s Cancer Group 8891. J Clin Oncol. 2004;22(17):3563\u20139. https:\/\/doi.org\/10.1200\/JCO.2004.01.006.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1437_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1006\/gyno.1998.5047","volume":"70","author":"MA Dimopoulos","year":"1998","unstructured":"Dimopoulos MA, Papadopoulou M, Andreopoulou E, Papadimitriou C, Pavlidis N, Aravantinos G, Aspropotamitis A, Anagnostopoulos A, Fountzilas G, Michalas S, Pectacides D. Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study. Gynecol Oncol. 1998;70(1):70\u20134. https:\/\/doi.org\/10.1006\/gyno.1998.5047.","journal-title":"Gynecol Oncol"},{"issue":"30","key":"1437_CR10","doi-asserted-by":"publisher","first-page":"4862","DOI":"10.1200\/JCO.2006.06.2489","volume":"24","author":"N Murugaesu","year":"2006","unstructured":"Murugaesu N, Schmid P, Dancey G, Agarwal R, Holden L, McNeish I, Savage PM, Newlands ES, Rustin GJ, Seckl MJ. Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol. 2006;24(30):4862\u20136. https:\/\/doi.org\/10.1200\/JCO.2006.06.2489.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1437_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jso.21079","volume":"98","author":"JK Chan","year":"2008","unstructured":"Chan JK, Tewari KS, Waller S, Cheung MK, Shin JY, Osann K, Kapp DS. The influence of conservative surgical practices for malignant ovarian germ cell tumors. J Surg Oncol. 2008;98(2):111\u20136. https:\/\/doi.org\/10.1002\/jso.21079.","journal-title":"J Surg Oncol"},{"issue":"1","key":"1437_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000381771","volume":"81","author":"ZJ Yang","year":"2016","unstructured":"Yang ZJ, Liu ZC, Wei RJ, Li L. An analysis of prognostic factors in patients with ovarian malignant germ cell tumors who are treated with fertility-preserving surgery. Gynecol Obstet Invest. 2016;81(1):1\u20139. https:\/\/doi.org\/10.1159\/000381771.","journal-title":"Gynecol Obstet Invest"},{"key":"1437_CR13","doi-asserted-by":"crossref","unstructured":"Slayton RE, Park RC, Silverberg SG, Shingleton H, Creasman WT, Blessing JA. Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. A Gynecologic Oncology Group Study (a final report). Cancer. 1985;56(2):243\u20138. https:\/\/doi.org\/10.1002\/1097-0142(19850715)56:2<243::aid-cncr2820560206>3.0.co;2-t.","DOI":"10.1002\/1097-0142(19850715)56:2<243::AID-CNCR2820560206>3.0.CO;2-T"},{"issue":"3","key":"1437_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.5858\/arpa.2012-0547-RA","volume":"138","author":"FF Nogales","year":"2014","unstructured":"Nogales FF, Dulcey I, Preda O. Germ cell tumors of the ovary: an update. Arch Pathol Lab Med. 2014;138(3):351\u201362. https:\/\/doi.org\/10.5858\/arpa.2012-0547-RA.","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"1437_CR15","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1200\/JCO.1994.12.2.378","volume":"12","author":"E Segelov","year":"1994","unstructured":"Segelov E, Campbell J, Ng M, Tattersall M, Rome R, Free K, Hacker N, Friedlander ML. Cisplatin-based chemotherapy for ovarian germ cell malignancies: the Australian experience. J Clin Oncol. 1994;12(2):378\u201384. https:\/\/doi.org\/10.1200\/JCO.1994.12.2.378.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1437_CR16","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.1999.17.9.2670","volume":"17","author":"M Brewer","year":"1999","unstructured":"Brewer M, Gershenson DM, Herzog CE, Mitchell MF, Silva EG, Wharton JT. Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol. 1999;17(9):2670\u20135. https:\/\/doi.org\/10.1200\/JCO.1999.17.9.2670.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1437_CR17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/s0029-7844(02)02508-5","volume":"101","author":"J Tangir","year":"2003","unstructured":"Tangir J, Zelterman D, Ma W, Schwartz PE. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstet Gynecol. 2003;101(2):251\u20137. https:\/\/doi.org\/10.1016\/s0029-7844(02)02508-5.","journal-title":"Obstet Gynecol"},{"issue":"3","key":"1437_CR18","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.ygyno.2006.08.003","volume":"103","author":"T Maltaris","year":"2006","unstructured":"Maltaris T, Boehm D, Dittrich R, Seufert R, Koelbl H. Reproduction beyond cancer: a message of hope for young women. Gynecol Oncol. 2006;103(3):1109\u201321. https:\/\/doi.org\/10.1016\/j.ygyno.2006.08.003.","journal-title":"Gynecol Oncol"},{"issue":"19","key":"1437_CR19","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1200\/JCO.2006.08.4590","volume":"25","author":"DM Gershenson","year":"2007","unstructured":"Gershenson DM, Miller AM, Champion VL, Monahan PO, Zhao Q, Cella D, Williams SD. Gynecologic Oncology Group. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(19):2792\u20137. https:\/\/doi.org\/10.1200\/JCO.2006.08.4590.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1437_CR20","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/1097-0142(20000715)89:2<391::AID-CNCR26>3.0.CO;2-V","volume":"89","author":"JJ Low","year":"2000","unstructured":"Low JJ, Perrin LC, Crandon AJ, Hacker NF. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases. Cancer. 2000;89(2):391\u20138.","journal-title":"Cancer"},{"issue":"4","key":"1437_CR21","doi-asserted-by":"publisher","first-page":"385.e1","DOI":"10.1016\/j.ajog.2018.07.021","volume":"219","author":"S Tamauchi","year":"2018","unstructured":"Tamauchi S, Kajiyama H, Yoshihara M, Ikeda Y, Yoshikawa N, Nishino K, Utsumi F, Niimi K, Suzuki S, Kikkawa F. Reproductive outcomes of 105 malignant ovarian germ cell tumor survivors: a multicenter study. Am J Obstet Gynecol. 2018;219(4):385.e1-385.e7. https:\/\/doi.org\/10.1016\/j.ajog.2018.07.021.","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"1437_CR22","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1200\/JCO.1994.12.4.701","volume":"12","author":"S Williams","year":"1994","unstructured":"Williams S, Blessing JA, Liao SY, Ball H, Hanjani P. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. J Clin Oncol. 1994;12(4):701\u20136. https:\/\/doi.org\/10.1200\/JCO.1994.12.4.701.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1437_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.7326\/0003-4819-111-1-22","volume":"111","author":"SD Williams","year":"1989","unstructured":"Williams SD, Blessing JA, Moore DH, Homesley HD, Adcock L. Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors. A trial of the Gynecologic Oncology Group. Ann Intern Med. 1989;111(1):22\u20137. https:\/\/doi.org\/10.7326\/0003-4819-111-1-22.","journal-title":"Ann Intern Med"},{"key":"1437_CR24","doi-asserted-by":"crossref","unstructured":"Gershenson DM, Copeland LJ, Kavanagh JJ, Cangir A, Del Junco G, Saul PB, Stringer CA, Freedman RS, Edwards CL, Wharton JT. Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vincristine, dactinomycin, and cyclophosphamide. Cancer. 1985;56(12):2756\u201361. https:\/\/doi.org\/10.1002\/1097-0142(19851215)56:12%3c2756::aid-cncr2820561206%3e3.0.co;2-6.","DOI":"10.1002\/1097-0142(19851215)56:12<2756::AID-CNCR2820561206>3.0.CO;2-6"},{"issue":"10","key":"1437_CR25","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1200\/JCO.1983.1.10.645","volume":"1","author":"RW Carlson","year":"1983","unstructured":"Carlson RW, Sikic BI, Turbow MM, Ballon SC. Combination cisplatin, vinblastine, and bleomycin chemotherapy (PVB) for malignant germ-cell tumors of the ovary. J Clin Oncol. 1983;1(10):645\u201351. https:\/\/doi.org\/10.1200\/JCO.1983.1.10.645.","journal-title":"J Clin Oncol"},{"key":"1437_CR26","doi-asserted-by":"crossref","unstructured":"Taylor MH, Depetrillo AD, Turner AR. Vinblastine, bleomycin, and cisplatin in malignant germ cell tumors of the ovary. Cancer. 1985;56(6):1341\u20139. https:\/\/doi.org\/10.1002\/1097-0142(19850915)56:6%3c1341::aid-cncr2820560621%3e3.0.co;2-2.","DOI":"10.1002\/1097-0142(19850915)56:6<1341::AID-CNCR2820560621>3.0.CO;2-2"},{"issue":"3","key":"1437_CR27","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/oxfordjournals.annonc.a058797","volume":"5","author":"JI Mayordomo","year":"1994","unstructured":"Mayordomo JI, Paz-Ares L, Rivera F, L\u00f3pez-Brea M, L\u00f3pez Mart\u00edn E, Mendiola C, D\u00edaz-Puente MT, Lianes P, Garc\u00eda-Prats MD, Cort\u00e9s-Funes H. Ovarian and extragonadal malignant germ-cell tumors in females: a single-institution experience with 43 patients. Ann Oncol. 1994;5(3):225\u201331. https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a058797.","journal-title":"Ann Oncol"},{"issue":"4","key":"1437_CR28","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1200\/JCO.2001.19.4.1015","volume":"19","author":"G Zanetta","year":"2001","unstructured":"Zanetta G, Bonazzi C, Cant\u00f9 M, Binidagger S, Locatelli A, Bratina G, Mangioni C. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol. 2001;19(4):1015\u201320. https:\/\/doi.org\/10.1200\/JCO.2001.19.4.1015.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1437_CR29","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s00404-020-05522-5","volume":"301","author":"M Miku\u0161","year":"2020","unstructured":"Miku\u0161 M, Benco N, Matak L, Planini\u0107 P, \u0106ori\u0107 M, Lovri\u0107 H, Rado\u0161evi\u0107 V, Pu\u017eevski T, Bajt M, Vuji\u0107 G. Fertility-sparing surgery for patients with malignant ovarian germ cell tumors: 10 years of clinical experience from a tertiary referral center. Arch Gynecol Obstet. 2020;301(5):1227\u201333. https:\/\/doi.org\/10.1007\/s00404-020-05522-5.","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"1437_CR30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/GRF.0b013e318248045b","volume":"55","author":"DM Gershenson","year":"2012","unstructured":"Gershenson DM. Treatment of ovarian cancer in young women. Clin Obstet Gynecol. 2012;55(1):65\u201374. https:\/\/doi.org\/10.1097\/GRF.0b013e318248045b.","journal-title":"Clin Obstet Gynecol"},{"issue":"2","key":"1437_CR31","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ygyno.2013.08.028","volume":"131","author":"O Solheim","year":"2013","unstructured":"Solheim O, K\u00e6rn J, Trop\u00e9 CG, Rokkones E, Dahl AA, Nesland JM, Foss\u00e5 SD. Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953\u20132009). Gynecol Oncol. 2013;131(2):330\u20135. https:\/\/doi.org\/10.1016\/j.ygyno.2013.08.028.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1437_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4103\/sajc.sajc_6_18","volume":"8","author":"R Agarwal","year":"2019","unstructured":"Agarwal R, Rajanbabu A, Keechilattu P, Nair IR, Vijaykumar DK, Unnikrishnan UG. A retrospective analysis of the pattern of care and survival in patients with malignant ovarian germ cell tumors. South Asian J Cancer. 2019;8(1):35\u201340. https:\/\/doi.org\/10.4103\/sajc.sajc_6_18.","journal-title":"South Asian J Cancer"},{"issue":"20","key":"1437_CR33","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2007.10.8738","volume":"25","author":"DM Gershenson","year":"2007","unstructured":"Gershenson DM. Management of ovarian germ cell tumors. J Clin Oncol. 2007;25(20):2938\u201343. https:\/\/doi.org\/10.1200\/JCO.2007.10.8738.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1437_CR34","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3109\/09513590.2014.907262","volume":"30","author":"A Gadducci","year":"2014","unstructured":"Gadducci A, Lanfredini N, Tana R. Menstrual function and childbearing potential after fertility-sparing surgery and platinum-based chemotherapy for malignant ovarian germ cell tumours. Gynecol Endocrinol. 2014;30(7):467\u201371. https:\/\/doi.org\/10.3109\/09513590.2014.907262.","journal-title":"Gynecol Endocrinol"},{"issue":"3","key":"1437_CR35","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ygyno.2017.03.023","volume":"145","author":"JY Park","year":"2017","unstructured":"Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH. Analysis of outcomes and prognostic factors after fertility-sparing surgery in malignant ovarian germ cell tumors. Gynecol Oncol. 2017;145(3):513\u20138. https:\/\/doi.org\/10.1016\/j.ygyno.2017.03.023.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1437_CR36","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.ygyno.2010.12.351","volume":"121","author":"CA Parkinson","year":"2011","unstructured":"Parkinson CA, Hatcher HM, Earl HM, Ajithkumar TV. Multidisciplinary management of malignant ovarian germ cell tumours. Gynecol Oncol. 2011;121(3):625\u201336. https:\/\/doi.org\/10.1016\/j.ygyno.2010.12.351.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"1437_CR37","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3802\/jgo.2014.25.4.320","volume":"25","author":"A Ditto","year":"2014","unstructured":"Ditto A, Martinelli F, Lorusso D, Haeusler E, Carcangiu M, Raspagliesi F. Fertility sparing surgery in early stage epithelial ovarian cancer. J Gynecol Oncol. 2014;25(4):320\u20137. https:\/\/doi.org\/10.3802\/jgo.2014.25.4.320.","journal-title":"J Gynecol Oncol"},{"issue":"1","key":"1437_CR38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1525-1438.2007.00969.x","volume":"18","author":"DM Patterson","year":"2008","unstructured":"Patterson DM, Murugaesu N, Holden L, Seckl MJ, Rustin GJ. A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites. Int J Gynecol Cancer. 2008;18(1):43\u201350. https:\/\/doi.org\/10.1111\/j.1525-1438.2007.00969.x.","journal-title":"Int J Gynecol Cancer"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-021-01437-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-021-01437-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-021-01437-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T09:04:36Z","timestamp":1628067876000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-021-01437-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,4]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1437"],"URL":"https:\/\/doi.org\/10.1186\/s12905-021-01437-8","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,4]]},"assertion":[{"value":"20 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained by the ethics committee of the Imam Khomeini Hospital Complex, Tehran University of Medical Sciences (TUMS) with ethical codes. TUMS.IKHC.REC.1397.256, and all methods were carried out following relevant guidelines and regulations. Informed consent to participate in the study was obtained from all the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There are no conflicts of interest to disclose of all authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"282"}}